South Africa Respiratory Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The south africa respiratory devices market size is projected to expand from USD 213.91 million in 2025 and USD 227.26 million in 2026 to USD 302.31 million by 2031, registering a CAGR of 5.87% between 2026 to 2031. This report is Segmented by Product Type (Diagnostic & Monitoring Devices, Therapeutic Devices, Disposables), Application (COPD, Asthma, Sleep Apnea, Tuberculosis, Other), End User (Hospitals & Clinics, Home Healthcare Settings, Ambulatory Surgical Centers, Other), and Geography (South Africa). Market Forecasts are Provided in Terms of Value (USD).

South Africa Respiratory Devices Market Trends and Insights

Rising Prevalence of COPD, Asthma, TB & Sleep Apnea

Tuberculosis notifications fell from 450,000 in 2015 to about 230,000 in 2022, yet drug-resistant strains sustain the need for portable nebulizers in community clinics. Sleep apnea affects 29.3% of rural older adults but remains underdiagnosed in urban areas, leaving a sizeable potential for PAP therapy expansion. Biomass-fuel exposure and post-TB airway damage elevate COPD risk, driving oxygen-concentrator rentals across informal settlements. The prevalence of urban childhood asthma, reaching up to 20%, signals an ongoing demand for peak-flow meters and inhalers as primary care infrastructure expands. Population aging and deteriorating air quality in industrial corridors ensure these diseases remain the main demand anchor through 2031.

Increasing Adoption of Home-Care & Portable Devices

The National Health Insurance (NHI) Act prioritizes decentralized care, promoting the use of portable concentrators weighing under 3 kg for enhancing mobility and load-shedding resilience. Private medical schemes reimburse home PAP therapy at rates up to 50% lower than facility-based titration, incentivizing clinics to prescribe auto-adjusting devices that minimize follow-up visits. Nebulizer rentals bundled with nursing services cut readmissions by roughly 20% at leading hospital groups. Frequent power interruptions reported by 30% to 40% of home-care patients make battery backup a must-have specification. User-friendly interfaces and six-month filter-replacement intervals cater to caregivers in multigenerational households.

High Upfront Cost & Import Dependency of Advanced Devices

More than 90% of respiratory devices are imported, making landed prices vulnerable to currency swings and customs duties. ICU ventilators that leave factories at USD 25,000 to USD 35,000 reach USD 50,000 after taxes and logistics. Median household income constraints force many sleep-apnea patients to rent PAP units for ZAR 800-1,200 per month. The 2024 Medical Devices Localization Strategy offers tax credits to spur the assembly of ventilators and concentrators; however, uptake remains slow due to unclear regulatory pathways for locally built units. Rand depreciation averaging 8% to 12% annually further stretches replacement cycles to seven years and drives demand for refurbished imports.

Other drivers and restraints analyzed in the detailed report include:

• Technological Advances: AI-Enabled & Connected Devices
• Growth in Tele-Respiratory & Remote-Monitoring Services
• Electricity-Supply Instability Impacting Device Uptime

Segment Analysis

The South Africa respiratory devices market size for disposables is growing faster than any other category, expanding at an 8.72% CAGR to 2031 as single-use masks and breathing circuits become mandatory in revised hospital protocols. Therapeutic devices retained a 46.31% revenue share in 2025, primarily driven by the installation of ventilators and PAP units during pandemic-era upgrades. Ventilators such as the Carescape R860 and Evita V800 lead ICU budgets due to their lung-protective modes, which lower the risk of barotrauma. CPAP systems, spearheaded by AirSense 11 and DreamStation 2, account for roughly one-third of therapeutic revenue as diagnostic labs double output. Portable battery-powered concentrators captured 40% of fresh home-therapy placements in 2025, underscoring consumer preference for mobility amid load shedding.

Private pulmonologists invest in handheld spirometers, shortening the diagnosis-to-treatment window from four weeks to same-day initiation. Smart inhalers with Bluetooth-enabled adherence logs are awaiting SAHPRA clearance, creating pent-up demand among asthma specialists. Local assembly of entry-level nebulizers could shave prices by 20%, positioning domestic firms for public tenders that favor local content. Overall, tightening infection-control rules and a push toward local manufacturing position disposables and basic therapeutic devices for above-market growth.

Complete Report Scope:

• By Product Type
  • Diagnostic & Monitoring Devices
    • Spirometers
    • Sleep Test Devices
    • Peak Flow Meters
    • Pulse Oximeters
    • Capnographs
    • Other Diagnostic & Monitoring Devices
  • Therapeutic Devices
    • CPAP Devices
    • BiPAP Devices
    • Humidifiers
    • Nebulizers
    • Oxygen Concentrators
    • Ventilators
    • Inhalers
    • Other Therapeutic Devices
  • Disposables
    • Masks
    • Breathing Circuits
    • Other Disposables
• By Application
  • COPD
  • Asthma
  • Sleep Apnea
  • Tuberculosis
  • Other Application
• By End User
  • Hospitals & Clinics
  • Home Healthcare Settings
  • Ambulatory Surgical Centers
  • Other End Users

List of Companies Covered in this Report:

• Akacia Medical & Healthcare Group
• BMC Medical
• Caire
• Dragerwerk
• Drive DeVilbiss Healthcare
• Fisher & Paykel Healthcare
• GE Healthcare
• Getinge AB (Maquet)
• Hamilton Bonaduz AG (Hamilton Medical)
• Inogen Inc.
• Invacare
• Koninklijke Philips
• Masimo
• MED-EL
• Medtronic
• Mindray
• Nihon Kohden
• OMRON
• Resmed
• Smiths Group
• Teleflex
• Vyaire Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support